全文获取类型
收费全文 | 34097篇 |
免费 | 1973篇 |
国内免费 | 739篇 |
专业分类
耳鼻咽喉 | 353篇 |
儿科学 | 727篇 |
妇产科学 | 1140篇 |
基础医学 | 8332篇 |
口腔科学 | 765篇 |
临床医学 | 2413篇 |
内科学 | 3278篇 |
皮肤病学 | 537篇 |
神经病学 | 2087篇 |
特种医学 | 758篇 |
外科学 | 1863篇 |
综合类 | 3241篇 |
预防医学 | 4194篇 |
眼科学 | 897篇 |
药学 | 3770篇 |
6篇 | |
中国医学 | 380篇 |
肿瘤学 | 2068篇 |
出版年
2023年 | 350篇 |
2022年 | 650篇 |
2021年 | 930篇 |
2020年 | 916篇 |
2019年 | 894篇 |
2018年 | 943篇 |
2017年 | 993篇 |
2016年 | 939篇 |
2015年 | 1061篇 |
2014年 | 1983篇 |
2013年 | 2101篇 |
2012年 | 1814篇 |
2011年 | 2164篇 |
2010年 | 1671篇 |
2009年 | 1709篇 |
2008年 | 1754篇 |
2007年 | 1634篇 |
2006年 | 1438篇 |
2005年 | 1182篇 |
2004年 | 1059篇 |
2003年 | 969篇 |
2002年 | 717篇 |
2001年 | 680篇 |
2000年 | 656篇 |
1999年 | 595篇 |
1998年 | 589篇 |
1997年 | 553篇 |
1996年 | 569篇 |
1995年 | 571篇 |
1994年 | 543篇 |
1993年 | 452篇 |
1992年 | 443篇 |
1991年 | 371篇 |
1990年 | 341篇 |
1989年 | 300篇 |
1988年 | 271篇 |
1987年 | 217篇 |
1986年 | 174篇 |
1985年 | 262篇 |
1984年 | 248篇 |
1983年 | 155篇 |
1982年 | 151篇 |
1981年 | 141篇 |
1980年 | 121篇 |
1979年 | 109篇 |
1978年 | 84篇 |
1977年 | 70篇 |
1976年 | 57篇 |
1975年 | 36篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
1.
2.
3.
目的:了解2011-2017年四川省三州地区卫生人力资源配置现状,为三州地区卫生人力资源的合理配置提供参考。方法:利用千人卫生人力资源拥有量指标、基尼系数和卫生人力资源密度指数(HRDI)分析卫生人力资源配置现状及其公平性。结果:三州地区千人卫生人力资源拥有量呈增长趋势;基尼系数大多超过0.4,仅护士按人口分布的基尼系数较小;卫生人力资源密度指数较小,需要量、缺乏量及缺乏比例均较大。结论:三州地区卫生人力得到一定程度改善;但配置公平性较差,尤其按地理、经济分布很不均衡;医护人员短缺,需要重点投入。 相似文献
4.
内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。 相似文献
5.
6.
7.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
8.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
9.
《Saudi Pharmaceutical Journal》2022,30(6):655-668
Most vaccines approved by regulatory bodies are administered via intramuscular or subcutaneous injections and have shortcomings, such as the risk of needle-associated blood infections, pain and swelling at the injection site. Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. Hence, oral vaccination can eliminate the injection associated adverse effects and enhance the person's compliance. Conventional approaches to manufacturing oral vaccines, such as coacervation, spray drying, and membrane emulsification, tend to alter the structural proteins in vaccines that result from high temperature, organic and toxic solvents during production. Electrohydrodynamic processes, specifically electrospraying, could solve these challenges, as it also modulates antigen release and has a high loading efficiency. This review will highlight the mucosal immunity and biological basis of the gastrointestinal immune system, different oral vaccine delivery approaches, and the application of electrospraying in vaccines development. 相似文献
10.